28 reports

Cancer Diagnostics Market Analysis By Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), By Application (Breast, Lung, Liver, Cervical, Colorectal, Skin), By Region, And Segment Forecasts, 2014 - 2025 Table of Contents Chapter ## Research Methodology ##. ## Information procurement ##. ##

  • Cancer Diagnostic
  • Diagnostics
  • Forecast
  • GENETIC TESTS SALES AND FORECASTS (BILLION YUAN)
  • Molecular Diagnostics
  • Cancer Diagnostic
  • Diagnostics
  • Healthcare
  • China
  • Demand
  • Genetic Tests Sales and Forecasts (Billion Yuan)
  • III
  • Cancer Diagnostic
  • China
  • Demand
  • Market Size
  • Hitachi, Ltd.
  • Global cancer diagnostic devices market segmentation by cancer type 2015
  • Key vendors

Offers molecular diagnostics with genetic testing of micro-organisms- and genetic-based diseases to various institutions.

  • Cancer Diagnostic
  • World
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Roche Group
  • III
  • Cancer Diagnostics Sales Volumes and Forecasts

BGI ALSO OFFERS A WIDE PORTFOLIO OF TRANSFORMATIVE GENETIC TESTING PRODUCTS ACROSS MAJOR DISEASES, ENABLING MEDICAL PROVIDERS AND PATIENTS WORLDWIDE TO REALIZE THE PROMISE OF GENOMICS-BASED DIAGNOSTICS AND PERSONALIZED BGI (Shenzhen) Co., Ltd Chapter VII CANCER DIAGNOSTICS PRODUCER DIRECTOR

  • Cancer Diagnostic
  • China
  • Beijing Shimadzu Medical Equipment Co., Ltd.
  • GE Medical Systems Co., Ltd
  • Hitachi, Ltd.
  • GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY VALUE, 2016E-2021F
  • TUMOUR MARKER TEST MARKET, BY VALUE, 2011-2021F

These tests use genetic samples that are used to identify any symptoms of cancer at early stages.

  • Cancer Diagnostic
  • Market Size
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company, Ltd

Based on application market is categorized into biomarker development, proteomic analysis, genetic analysis, CTC analysis and epigenetic analysis.

  • Cancer
  • Cancer Diagnostic
  • World
  • Forecast
  • Market Size

genetic sequencing ##. ##. ##. ## Development of cluster chip technology and potential applications of CTC in cancer management ##. ##. ##. ## Rising demand for preventive medicine & companion diagnostics ##. ##. ##. ## Growing cancer incidence ##. ##. ## Market restraint analysis ##. ##. ##. ## Requirement of expensiv

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Market Size

OncoCyte' s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.

  • Cancer
  • Cancer Diagnostic
  • World
  • Market Size
  • MetaStat, Inc.

Genetic Mutations ##. ## Companion Diagnostics (CDx) ##. ## Laboratory Developed Test (LDT) ##. ## Precision Medicine ##. ## Government Regulations ##. ##. ## The US Approval and Regulation System ##. ##. ## The EU Approval and Regulation System ##. ## Market Definition ##.

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Market Size

Genetic - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher - Veridex - Wako

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Company Sales
  • Demand

Genetic - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher - Veridex - Wako

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Demand

Genetic - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher - Veridex - Wako

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Demand

Genetic Analysis ##. ## Biomarker Development ##. ## CTC Analysis ## Global Next Generation Cancer Diagnostics Market, By Technology ##. ## Introduction ##. ## Lab-on-a-chip ##. ## DNA Microarrays ##. ## Multiplexed assays ##. ## RT-PCR & Multiplexing ##. ## Protein Microarrays ##. ## Cellular capture and identif

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Forecast

Genetic - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher - Veridex - Wako

  • Cancer Diagnostic
  • Diagnostics
  • World
  • Demand

(an Invivoscribe company) GeneDx GeneNews Limited Genetic Technologies Limited / Phenogen Sciences, Inc.

  • Cancer Diagnostic
  • Diagnostics
  • World

Genetic Analysis ##. ##. ##.

  • Cancer Diagnostic
  • Diagnostics
  • Forecast

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer Diagnostic
  • Therapy
  • Demand
  • Market Segment
  • Market Size
  • Date
  • CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY REGION, 2013-2020 ($MILLION)

Transcriptome profiling helps analyze genetic variants after cell expression.

  • Cancer Diagnostic
  • GE Healthcare Limited
  • Illumina, Inc.
  • QIAGEN N.V.
  • Roche Group

The intersection of artificial intelligence with genetic treatments for cancer represents a significant market opportunity.

  • Cancer Diagnostic
  • United States
  • World
  • Market Size
  • GE Healthcare Limited

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer Diagnostic
  • Diagnostics
  • Japan

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer Diagnostic
  • Diagnostics
  • Japan

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer Diagnostic
  • Diagnostics
  • Japan

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer Diagnostic
  • Diagnostics
  • Japan

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.

  • Cancer
  • Cancer Diagnostic
  • Monoclonal Antibody
  • Demand
  • Market Size
  • MEDITE CANCER DIAGNOSTICS INC PIPELINE PRODUCTS BY DEVELOPMENT STAGE

As of July, 2017 GENETIC BIOMARKER ASSAY - UTERINE CANCER GENETIC BIOMARKER ASSAY - UTERINE CANCER PRODUCT OVERVIEW GENETIC BIOMARKER ASSAY - UTERINE CANCER - PRODUCT STATUS Market Category Developed By Pipeline Territory Highest Stage of Development Device Class Regulator

  • Cancer
  • Cancer Diagnostic
  • United States
  • Company
  • MEDITE Cancer Diagnostics, Inc.
  • 4.3 SELECTED CNA CANCER DIAGNOSTIC PRODUCTS

The programs span genetic, expression, epigenetic and other markers.

  • Cancer Diagnostic
  • RNA
  • Affymetrix, Inc.
  • QIAGEN N.V.
  • Roche Group

Dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials.

  • Cancer
  • Cancer Diagnostic
  • Clinical Trial
  • United States
  • GlobalData's company